Arrowhead To Present At Upcoming Scientific Conferences

Arrowhead Research Corporation (NASDAQ: ARWR), a targeted therapeutics company, today announced that the company will present data on the Dynamic PolyConjugate™ (DPC) siRNA delivery system and the ARC-520 hepatitis B drug candidate at three upcoming scientific conferences.

Scheduled conference presentations in June include the following:

The 18th Annual Meeting of the RNA Society – Davos, Switzerland, June 14, 2013

A workshop presentation titled, “ Development of Dynamic Polyconjugates for tissue-targeted delivery of siRNA,” will be presented by Christine Wooddell, Ph.D., Senior Scientist;

4th RNAi Research & Therapeutics Conference – San Francisco, CA, USA, June 21, 2013

A featured presentation titled, “ DPC Technology for siRNA Delivery: Moving from Platform to Pipeline,” will be presented by David Lewis, Ph.D., Vice President, Biology;

The European CLINAM and ETPN Summit, Clinical Nanomedicine and Targeted Medicine – Basel, Switzerland, June 26, 2013

An oral presentation titled, “ A Novel Hepatitis B Treatment with RNAi,” will be presented by Christopher Anzalone, Ph.D., President and CEO.

About Arrowhead Research Corporation

Arrowhead Research Corporation is a clinical stage targeted therapeutics company with development programs in oncology, obesity, and chronic hepatitis B virus. The company is leveraging its platform technologies to design and develop peptide-drug conjugates (PDCs) that specifically home to cell types of interest while sparing off-target tissues, create targeted drugs based on the gene silencing RNA interference (RNAi) mechanism, and work with partners to create improved versions of traditional small molecule drugs.

For more information please visit http://www.arrowheadresearch.com, or follow us on Twitter @ArrowRes. To be added to the Company's email list to receive news directly, please send an email to ir@arrowres.com

Copyright Business Wire 2010

If you liked this article you might like

Take a Look at These Stocks Poised to Trade Higher

These 5 Stocks Under $10 Could Explode Higher

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

The Worst Biopharma CEOs of 2016 Are ...